NASDAQ:IPSC

Century Therapeutics (IPSC) Stock Price, News & Analysis

$3.05
-0.04 (-1.29%)
(As of 04/22/2024 ET)
Today's Range
$2.98
$3.37
50-Day Range
$2.84
$5.32
52-Week Range
$1.28
$5.51
Volume
65,688 shs
Average Volume
202,245 shs
Market Capitalization
$197.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.60

Century Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
345.9% Upside
$13.60 Price Target
Short Interest
Bearish
7.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.32mentions of Century Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$127,635 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.94) to ($2.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.88 out of 5 stars

Medical Sector

589th out of 910 stocks

Biological Products, Except Diagnostic Industry

100th out of 154 stocks

IPSC stock logo

About Century Therapeutics Stock (NASDAQ:IPSC)

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

IPSC Stock Price History

IPSC Stock News Headlines

The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
Century Therapeutics: Q4 Earnings Insights
IPSC Century Therapeutics, Inc.
Century Therapeutics Inc (IPSC)
See More Headlines
Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
4/22/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IPSC
Fax
N/A
Employees
152
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.60
High Stock Price Target
$24.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+345.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-136,670,000.00
Net Margins
-6,115.12%
Pretax Margin
-6,030.96%

Debt

Sales & Book Value

Annual Sales
$2.24 million
Book Value
$3.09 per share

Miscellaneous

Free Float
59,892,000
Market Cap
$197.69 million
Optionable
Optionable
Beta
1.33
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Adrienne Farid Ph.D. (Age 62)
    COO & Head of Early Development
    Comp: $650.66k
  • Mr. Brent Pfeiffenberger M.B.A.
    Pharm.D., CEO & Director
  • Mr. Douglas Carr CPA
    Interim Principal Financial Officer, Senior VP of Finance & Operations and Secretary
  • Dr. Gregory Russotti Ph.D. (Age 57)
    Chief Technology & Manufacturing Officer
  • Mr. Kenneth J. Dow J.D.
    Senior VP of General Counsel
  • Dr. Shane Williams Ph.D.
    Chief People Officer
  • Dr. Hyam I. Levitsky M.D. (Age 66)
    President of Research & Development
    Comp: $502.12k
  • Michael Naso Ph.D.
    Senior VP of Cell Engineering
  • Dr. Nick Trede M.D.
    Ph.D., Senior VP & Head of Clinical Development

IPSC Stock Analysis - Frequently Asked Questions

Should I buy or sell Century Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IPSC shares.
View IPSC analyst ratings
or view top-rated stocks.

What is Century Therapeutics' stock price target for 2024?

5 brokers have issued 12-month price targets for Century Therapeutics' shares. Their IPSC share price targets range from $5.00 to $24.00. On average, they anticipate the company's stock price to reach $13.60 in the next twelve months. This suggests a possible upside of 345.9% from the stock's current price.
View analysts price targets for IPSC
or view top-rated stocks among Wall Street analysts.

How have IPSC shares performed in 2024?

Century Therapeutics' stock was trading at $3.32 on January 1st, 2024. Since then, IPSC shares have decreased by 8.1% and is now trading at $3.05.
View the best growth stocks for 2024 here
.

When is Century Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our IPSC earnings forecast
.

How were Century Therapeutics' earnings last quarter?

Century Therapeutics, Inc. (NASDAQ:IPSC) announced its quarterly earnings results on Thursday, March, 14th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.07. The company earned $0.27 million during the quarter, compared to analysts' expectations of $1.69 million. Century Therapeutics had a negative net margin of 6,115.12% and a negative trailing twelve-month return on equity of 54.73%.

When did Century Therapeutics IPO?

Century Therapeutics (IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

How do I buy shares of Century Therapeutics?

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IPSC) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners